SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Elder pharma strengthens on aiming Rs 100 crore from global sales of Shelcal by FY18

15 Jun 2015 Evaluate

Elder Pharmaceuticals is currently trading at Rs. 83.60, up by 4.20 points or 5.29% from its previous closing of Rs. 79.40 on the BSE.

The scrip opened at Rs. 82.00 and has touched a high and low of Rs. 85.80 and Rs. 82.00 respectively. So far 56195 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 226.85 on 13-Jun-2014 and a 52 week low of Rs. 66.65 on 10-Jun-2015.

Last one week high and low of the scrip stood at Rs. 85.80 and Rs. 66.65 respectively. The current market cap of the company is Rs. 170.87 crore.

The promoters holding in the company stood at 25.23% while Institutions and Non-Institutions held 26.29% and 48.47% respectively.

In a view of increasing exports base to Europe, Asia and African countries, Elder pharmaceuticals is aiming to garner Rs 100 crore from global sales of its calcium supplement brand Shelcal by 2017-18. The company had sold Shelcal’s domestic market rights and 30 other brands to Torrent group last year for Rs 2,000 crore but had retained the rights for the international markets.

The company is also looking to export another nutritional product,Thrive, a natural supplement that helps fight chronic metabolic disorders. It is looking at strong prescription base in over 70 countries by March 2017.

Elder Pharmaceuticals has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.

 

Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×